BACKGROUND: The role of herpes simplex virus type 2 (HSV-2) in the HIV epidemic and the potential impact of HSV-2 suppressive therapy have previously been explored only within the context of sub-Saharan Africa. In this analysis, modelling is used to estimate the contribution of HSV-2 to HIV transmission from clients to female sex workers (FSW) in a southern Indian setting and the maximum potential impact of 'perfect' HSV-2 suppressive therapy on HIV incidence. METHODS: A dynamic HSV-2/HIV model was developed, parameterised and fitted to Mysore data. The model estimated the attributable fractions of HIV infections due to HSV-2. Multivariate sensitivity analyses and regression analyses were conducted. RESULTS: The model suggests that 36% (95% CI 22% to 62%) of FSW HIV infections were due to HSV-2, mostly through HSV-2 asymptomatic shedding. Even if HSV-2 suppressive therapy could eliminate the effect of HSV-2 on HIV infectivity among all co-infected clients, only 15% (95% CI 3% to 41%) of HIV infections among FSW would have been averted. 36% (95% CI 18% to 61%) of HIV infections among HSV-2-infected FSW could have been averted if suppressive therapy reduced their risk of HIV acquisition to that of HSV-2-uninfected FSW. CONCLUSIONS: HSV-2 contributes substantially to HIV in this southern Indian context. However, even in the best case scenario, HSV-2 suppressive therapy is unlikely to reduce HIV transmission or acquisition by more than 50% (as aimed for in recent trials), because of the limited strength of the interaction effect between HSV-2 and HIV.
BACKGROUND: The role of herpes simplex virus type 2 (HSV-2) in the HIV epidemic and the potential impact of HSV-2 suppressive therapy have previously been explored only within the context of sub-Saharan Africa. In this analysis, modelling is used to estimate the contribution of HSV-2 to HIV transmission from clients to female sex workers (FSW) in a southern Indian setting and the maximum potential impact of 'perfect' HSV-2 suppressive therapy on HIV incidence. METHODS: A dynamic HSV-2/HIV model was developed, parameterised and fitted to Mysore data. The model estimated the attributable fractions of HIV infections due to HSV-2. Multivariate sensitivity analyses and regression analyses were conducted. RESULTS: The model suggests that 36% (95% CI 22% to 62%) of FSW HIV infections were due to HSV-2, mostly through HSV-2 asymptomatic shedding. Even if HSV-2 suppressive therapy could eliminate the effect of HSV-2 on HIV infectivity among all co-infected clients, only 15% (95% CI 3% to 41%) of HIV infections among FSW would have been averted. 36% (95% CI 18% to 61%) of HIV infections among HSV-2-infected FSW could have been averted if suppressive therapy reduced their risk of HIV acquisition to that of HSV-2-uninfected FSW. CONCLUSIONS: HSV-2 contributes substantially to HIV in this southern Indian context. However, even in the best case scenario, HSV-2 suppressive therapy is unlikely to reduce HIV transmission or acquisition by more than 50% (as aimed for in recent trials), because of the limited strength of the interaction effect between HSV-2 and HIV.
Authors: Philippe Van de Perre; Michel Segondy; Vincent Foulongne; Abdoulaye Ouedraogo; Issouf Konate; Jean-Marie Huraux; Philippe Mayaud; Nicolas Nagot Journal: Lancet Infect Dis Date: 2008-08 Impact factor: 25.071
Authors: F X Mbopi-Kéou; G Grésenguet; P Mayaud; H A Weiss; R Gopal; M Matta; J L Paul; D W Brown; R J Hayes; D C Mabey; L Bélec Journal: J Infect Dis Date: 2000-09-08 Impact factor: 5.226
Authors: Anuradha Rebbapragada; Charles Wachihi; Christopher Pettengell; Sherzana Sunderji; Sanja Huibner; Walter Jaoko; Blake Ball; Keith Fowke; Tony Mazzulli; Francis A Plummer; Rupert Kaul Journal: AIDS Date: 2007-03-12 Impact factor: 4.177
Authors: Connie Celum; Anna Wald; James Hughes; Jorge Sanchez; Stewart Reid; Sinead Delany-Moretlwe; Frances Cowan; Martin Casapia; Abner Ortiz; Jonathan Fuchs; Susan Buchbinder; Beryl Koblin; Sheryl Zwerski; Scott Rose; Jing Wang; Lawrence Corey Journal: Lancet Date: 2008-06-21 Impact factor: 79.321
Authors: Jared M Baeten; Lara B Strick; Aldo Lucchetti; William L H Whittington; Jorge Sanchez; Robert W Coombs; Amalia Magaret; Anna Wald; Lawrence Corey; Connie Celum Journal: J Infect Dis Date: 2008-12-15 Impact factor: 5.226
Authors: M Augenbraun; J Feldman; K Chirgwin; J Zenilman; L Clarke; J DeHovitz; S Landesman; H Minkoff Journal: Ann Intern Med Date: 1995-12-01 Impact factor: 25.391
Authors: Esther E Freeman; Helen A Weiss; Judith R Glynn; Pamela L Cross; James A Whitworth; Richard J Hayes Journal: AIDS Date: 2006-01-02 Impact factor: 4.177
Authors: Jia Zhu; David M Koelle; Jianhong Cao; Julio Vazquez; Meei Li Huang; Florian Hladik; Anna Wald; Lawrence Corey Journal: J Exp Med Date: 2007-02-26 Impact factor: 14.307
Authors: Esther E Freeman; Richard G White; Roel Bakker; Kate K Orroth; Helen A Weiss; Anne Buvé; Richard J Hayes; Judith R Glynn Journal: Vaccine Date: 2008-12-09 Impact factor: 3.641
Authors: Fern Terris-Prestholt; Anna M Foss; Andrew P Cox; Lori Heise; Gesine Meyer-Rath; Sinead Delany-Moretlwe; Thomas Mertenskoetter; Helen Rees; Peter Vickerman; Charlotte H Watts Journal: BMC Infect Dis Date: 2014-01-09 Impact factor: 3.090
Authors: Ian H Spicknall; Katharine J Looker; Sami L Gottlieb; Harrell W Chesson; Joshua T Schiffer; Jocelyn Elmes; Marie-Claude Boily Journal: Vaccine Date: 2018-04-04 Impact factor: 3.641
Authors: Romain Silhol; Helen Coupland; Rebecca F Baggaley; Lori Miller; Lisa Staadegaard; Sami L Gottlieb; James Stannah; Katherine M E Turner; Peter Vickerman; Richard Hayes; Philippe Mayaud; Katharine J Looker; Marie-Claude Boily Journal: J Acquir Immune Defic Syndr Date: 2021-09-01 Impact factor: 3.771
Authors: Maria Xiridou; Henrike J Vriend; Anna K Lugner; Jacco Wallinga; Johannes S Fennema; Jan M Prins; Suzanne E Geerlings; Bart J A Rijnders; Maria Prins; Henry J C de Vries; Maarten J Postma; Maaike G van Veen; Maarten F Schim van der Loeff; Marianne A B van der Sande Journal: BMC Infect Dis Date: 2013-09-18 Impact factor: 3.090